343798-02-7

Usage

Uses

Used in Metalworking Industry:
(1-benzotriazol-1-yl-propyl)-(4-trifluoroMethyl-phenyl)-aMine is used as a corrosion inhibitor and stabilizer for metal surfaces. Its amine nature and benzotriazole structure contribute to its effectiveness in protecting metal surfaces from degradation and corrosion, enhancing the longevity and performance of metal components in various applications.
Used in Plastics Industry:
In the plastics industry, (1-benzotriazol-1-yl-propyl)-(4-trifluoroMethyl-phenyl)-aMine is utilized as a UV absorber and light stabilizer. Its ability to absorb ultraviolet radiation and stabilize plastics against the effects of light exposure makes it a valuable additive for improving the durability and appearance of plastic products, particularly those that are exposed to sunlight or other light sources.
Used in Coatings Industry:
(1-benzotriazol-1-yl-propyl)-(4-trifluoroMethyl-phenyl)-aMine is also used in the coatings industry as a light stabilizer and UV absorber. Its incorporation into coating formulations helps to protect the coated surfaces from the damaging effects of sunlight and other environmental factors, thereby maintaining the integrity and appearance of the coatings and the substrates they protect.

Upstream product

• 95-14-7 1,2,3-Benzotriazole 
• 455-14-1 4-trifluoromethylphenylamine 
• 123-38-6 propionaldehyde 

Downstream Products

• 474645-93-7 (2R,4S)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamic acid methyl ester 
• 262352-17-0 torcetrapib 
• 474645-96-0 (2R,4S)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamic acid benzyl ester 

Relevant academic research and scientific papers

NONEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES

The present invention relates to a novel derivative of Compound 1 selectively substituted with fluorine and/or deuterium and optionally further substituted with deuterium and 13C elsewhere in the molecule. The compounds of this invention are cholesterol esterase transfer protein inhibitors and possess unique biopharmaceutical and pharmacokinetic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and tissues and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these compounds and methods of treating diseases and conditions that are responsive to inhibition of cholesterol esterase transfer protein, alone and in combination with additional agents.

Synthesis of the CETP inhibitor torcetrapib: The resolution route and origin of stereoselectivity in the iminium ion cyclization

A practical, efficient synthesis of (-)-(2R,4S)-4-[(3,5-bis- trifluoromethyl-benzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3, 4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester (1), a cholesteryl ester transfer protein (CETP) inhibitor, is desc

Inhibitors of cholesterol ester transfer protein

This invention relates to inhibitors of CETP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by CETP.

METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES

The present invention provides a method for producing optically active amines of formula (9) or (10): which comprises reacting an imine equivalent of formula (6): with an alkene of formula (7) or an alkyne of formula (8): in the presence of a chiral catal

Therapeutic combination

Pharmaceutical combinations of a CETP inhibitor and atorvastatin or hydroxy metabolites thereof or a pharmaceutically acceptable salt thereof, methods of using such combinations and kits containing such combinations for the treatment of atherosclerosis, a

Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline

Methods of preparing CETP inhibitors are disclosed.